W
Won Ki Kang
Researcher at Samsung Medical Center
Publications - 385
Citations - 18420
Won Ki Kang is an academic researcher from Samsung Medical Center. The author has contributed to research in topics: Cancer & Capecitabine. The author has an hindex of 59, co-authored 368 publications receiving 14746 citations. Previous affiliations of Won Ki Kang include Sungkyunkwan University & Samsung.
Papers
More filters
Journal ArticleDOI
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Hee Kyung Ahn,Soohyeon Lee,Jong Mu Sun,Jeeyun Lee,Se Hoon Park,Joon Oh Park,Young Suk Park,Won Ki Kang,Ho Yeong Lim +8 more
TL;DR: A retrospective study to evaluate the efficacy and safety of sequential administration of sunitinib following failure of sorafenib in advanced HCC patients and to define optimal strategy of sequential treatment.
Journal ArticleDOI
Phase III trial of a 3-weekly versus 5-weekly schedule of S-1 plus cisplatin (SP) combination chemotherapy for first-line treatment of advanced gastric cancer (AGC): SOS study.
Min-Hee Ryu,Eishi Baba,Kyung Hee Lee,Narikazu Boku,Young Iee Park,Ichinosuke Hyodo,Byung-Ho Nam,Taito Esaki,Baek-Yeol Ryoo,Eun-Kee Song,Sang-Hee Cho,Sung Sook Lee,Won Ki Kang,Sung Hyun Yang,Dae Young Zang,Dong Bok Shin,Sook Ryun Park,K. Shinozaki,Toshimi Takano,Yoon-Koo Kang +19 more
TL;DR: This SOS study was a multicenter, randomized, open-label, phase III study to evaluate whether SP3 was non-inferior/superior to SP5 in terms of progression-free survival (PFS) determined by a blinded central radiology review according to RECIST v1.1.
Journal ArticleDOI
First-line capecitabine (X) monotherapy versus capecitabine plus oxaliplatin (XELOX) in elderly patients with advanced gastric cancer (AGC): results from the first interim analysis.
In Gyu Hwang,Hyo Rak Lee,Hui-Young Lee,Jun Ho Ji,Jung Hun Kang,Soon Il Lee,Seung Tae Kim,Jeeyun Lee,Se Hoon Park,Won Ki Kang +9 more
TL;DR: The doublet combination with fluoropyrimidines and platinum is currently considered standard first-line chemotherapy in AGC, but there has been a price to pay in terms of toxicity.
Journal ArticleDOI
The Efficacy of the Frontline Platinum-based Combination Chemotherapy in Malignant Peritoneal Mesothelioma
Seung Tae Kim,Jun Young Park,Jeeyun Lee,Joon Oh Park,Young Suk Park,Ho Yeong Lim,Won Ki Kang,Se Hoon Park +7 more
TL;DR: The platinum-based combination chemotherapy showed moderate activity and a favorable toxicity profile as a frontline treatment for patients with malignant peritoneal mesothelioma and pemetrexed in combination with platinum showed improved survival outcomes as compared with other combination regimens combined with platinum.
Journal ArticleDOI
MET is overexpressed in microsatellite instability-high gastric carcinoma.
Jongmin Sim,You Jeong Heo,Hyunsik Bae,Hyeong Chan Shin,Binnari Kim,Junhun Cho,Seung Tae Kim,Jeeyun Lee,Won Ki Kang,Kyoung-Mee Kim +9 more
TL;DR: Combined MET overexpression/ PD-L1 predictive models showed that patients with MET+/PD-L 1+ showed the best prognosis for overall survival as compared to other groups.